ALGS - Aligos announces dosing initiation of patients in chronic hepatitis B trial

Aligos Therapeutics (ALGS) has started the dosing in the first cohort of chronic hepatitis B (“CHB”) patients in the ongoing ALG-000184-201 study which is designed to evaluate the safety and efficacy of ALG-000184 in patients with CHB.The Phase 1 proof-of-concept study will assess the safety, pharmacokinetics ("PK"), and antiviral activity of up to 28 daily oral doses of ALG-000184 in untreated CHB patients as well as in those who are not currently undergoing treatment.The company intends to first establish the proof of concept as monotherapy in the Phase 1 trial before evaluating the treatment in combination in subsequent trials.Previously, an initial study of up to 7 oral daily doses in 48 healthy volunteers has demonstrated a good safety and PK profile for ALG-000184 including drug levels capable of achieving antiviral activity.The dosing initiation of that was announced in October. After a ~34% rise since its IPO, Aligos is facing the expiry of its lock-up

For further details see:

Aligos announces dosing initiation of patients in chronic hepatitis B trial